Pharmacies that make customized medications are asking the federal Food and Drug Administration to protect their right to ...

and that has included semaglutide and tirzepatide, the main ingredients in two different FDA-approved diabetes and weight loss drugs. “I did my research, and found what I believed to be a reputable ...

With brand-name GLP-1s for obesity treatment on and off the shortage list, prescribing can get complicated. Five providers ...

Novo said in a statement it wanted to ensure patients only received FDA-approved, safe, and effective semaglutide products.

US Food and Drug Administration (FDA) regulations allow human drug compounding — in which licensed pharmacists or physicians can combine, mix, or adjust the ingredients of a medication — to meet ...

Compounded semaglutide: Medication produced by compounded pharmacies ... A telehealth provider that can prescribe GLP-1 ...

The FDA removed Wegovy, Ozempic, Mounjaro, and Zepbound from its drug shortage list for the first time in two years. The move could jeopardize the availability of cheaper, generic forms of those drugs ...

Since Eli Lilly's Mounjaro and Novo Nordisk's Wegovy and Ozempic fell into shortage in late 2022, compounding pharmacies have been manufacturing their respective generics, tirzepatide and semaglutide.

Semaglutide has been on the FDA's shortage list since 2022, which has enabled compounding pharmacies and manufactures to make their own, unapproved versions of the drug. Novo Nordisk in October ...

Novo Nordisk’s CEO has alerted healthcare professionals about the growing risks associated with compounded semaglutide, a ...

“Patients who believe that they’re getting access to a safe product, and they believe they’re getting semaglutide … I know ...

Compounded versions of semaglutide, the active ingredient in approved diabetes ... Scott Brunner, CEO of the Alliance for ...